FR25C1021I1 - Composés et compositions destinés à moduler les activités kinase de l'egfr mutant - Google Patents

Composés et compositions destinés à moduler les activités kinase de l'egfr mutant

Info

Publication number
FR25C1021I1
FR25C1021I1 FR25C1021C FR25C1021C FR25C1021I1 FR 25C1021 I1 FR25C1021 I1 FR 25C1021I1 FR 25C1021 C FR25C1021 C FR 25C1021C FR 25C1021 C FR25C1021 C FR 25C1021C FR 25C1021 I1 FR25C1021 I1 FR 25C1021I1
Authority
FR
France
Prior art keywords
modulating
compositions
compounds
mutant egfr
kinase activities
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR25C1021C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yuhan Corp
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55654993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR25C1021(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of FR25C1021I1 publication Critical patent/FR25C1021I1/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quick-Acting Or Multi-Walled Pipe Joints (AREA)
FR25C1021C 2014-10-13 2025-06-03 Composés et compositions destinés à moduler les activités kinase de l'egfr mutant Active FR25C1021I1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462063394P 2014-10-13 2014-10-13
PCT/KR2015/010784 WO2016060443A2 (en) 2014-10-13 2015-10-13 Compounds and compositions for modulating egfr mutant kinase activities

Publications (1)

Publication Number Publication Date
FR25C1021I1 true FR25C1021I1 (fr) 2025-08-01

Family

ID=55654993

Family Applications (1)

Application Number Title Priority Date Filing Date
FR25C1021C Active FR25C1021I1 (fr) 2014-10-13 2025-06-03 Composés et compositions destinés à moduler les activités kinase de l'egfr mutant

Country Status (30)

Country Link
US (2) US9593098B2 (enExample)
EP (4) EP3207035B1 (enExample)
JP (3) JP6524221B2 (enExample)
KR (5) KR20240074820A (enExample)
CN (2) CN111686110B (enExample)
AU (1) AU2015331166B2 (enExample)
BR (1) BR112017007769B1 (enExample)
CA (1) CA2962914C (enExample)
CY (2) CY1122737T1 (enExample)
DK (3) DK3207035T3 (enExample)
ES (3) ES2879474T3 (enExample)
FI (2) FI3929190T3 (enExample)
FR (1) FR25C1021I1 (enExample)
HR (3) HRP20250213T1 (enExample)
HU (4) HUE054848T2 (enExample)
LT (4) LT3207035T (enExample)
MX (3) MX2017003181A (enExample)
NL (1) NL301329I2 (enExample)
NO (1) NO2025025I1 (enExample)
NZ (1) NZ730012A (enExample)
PH (1) PH12017500488A1 (enExample)
PL (3) PL3604294T3 (enExample)
PT (3) PT3207035T (enExample)
RS (3) RS61865B1 (enExample)
RU (1) RU2727700C2 (enExample)
SG (1) SG11201701960XA (enExample)
SI (3) SI3207035T1 (enExample)
SM (3) SMT202100266T1 (enExample)
TW (2) TWI730331B (enExample)
WO (1) WO2016060443A2 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20250213T1 (hr) 2014-10-13 2025-04-25 Yuhan Corporation Spojevi i pripravci za modulaciju aktivnosti egfr mutantne kinaze
US9938257B2 (en) 2015-09-11 2018-04-10 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
JP2019501222A (ja) 2016-01-07 2019-01-17 シーエス ファーマテック リミテッド Ｅｇｆｒチロシンキナーゼの臨床的に重要な変異体の選択的阻害薬
EP3464275B1 (en) 2016-05-26 2024-05-08 Recurium IP Holdings, LLC Egfr inhibitor compounds
KR102030886B1 (ko) * 2016-09-23 2019-10-10 재단법인 대구경북첨단의료산업진흥재단 신규한 이미다졸일 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
AR111469A1 (es) * 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
KR102388312B1 (ko) * 2017-06-13 2022-04-19 베이징 아다메이들 바이오테크놀로지 리미티드 라이어빌리티 컴퍼니 아미노피리미딘 화합물, 이의 제조방법 및 용도
DK3658552T3 (da) 2017-07-28 2023-11-20 Yuhan Corp Fremgangsmåde til fremstilling af n-(5-((4-(4-((dimethylamino)methyl)-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-yl)amino)-4-methoxy-2-morpholinophenyl)acrylamid ved reaktion af den tilsvarende amin med et 3-halogen-propionylchlorid
HUE059501T2 (hu) * 2017-07-28 2022-11-28 Yuhan Corp Aminopirimidin származékok elõállításához alkalmas intermedierek, eljárás elõállításukra, és eljárás aminopirimidin származékok elõállítására azok alkalmazásával
PT3658547T (pt) * 2017-07-28 2023-10-20 Yuhan Corp Processo de preparação de n -(5 -(4 -(4 -formil -3- fenil- 1h -pirazol- 1 -il)pirimidin -2- ilamino) -4 -metoxi 2- morfolinofenil) acrilamida
WO2019042187A1 (zh) 2017-08-30 2019-03-07 深圳市塔吉瑞生物医药有限公司 一种氨基嘧啶类化合物及包含该化合物的组合物及其用途
CN108047207A (zh) * 2018-01-30 2018-05-18 天津大学 N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-2-氟代丙烯酰胺氘代物及应用
CN108017633A (zh) * 2018-01-30 2018-05-11 天津大学 N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-2-氟代丙烯酰胺衍生物及应用
EP3849538A4 (en) 2018-09-10 2022-06-29 Mirati Therapeutics, Inc. Combination therapies
KR20200043618A (ko) * 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
CN111349084B (zh) * 2018-12-21 2022-11-25 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的氨基嘧啶类化合物
AU2020229467A1 (en) 2019-02-26 2021-08-12 Janssen Biotech, Inc. Combination therapies and patient stratification with bispecific anti-EGFR/c-met antibodies
PL3943491T3 (pl) * 2019-03-19 2025-11-17 Voronoi Inc. Pochodna heteroarylowa, sposób jej wytwarzania i kompozycja farmaceutyczna zawierająca ją jako skuteczny składnik
US12157730B2 (en) 2019-03-19 2024-12-03 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
CN111747950B (zh) 2019-03-29 2024-01-23 深圳福沃药业有限公司 用于治疗癌症的嘧啶衍生物
MX2021011810A (es) 2019-03-29 2021-10-26 Astrazeneca Ab Osimertinib para su uso en el tratamiento de cancer de pulmon de celulas no peque?as.
PH12021552798A1 (en) 2019-05-14 2022-09-19 Janssen Biotech Inc Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors
US11850248B2 (en) * 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
CA3140360A1 (en) * 2019-05-14 2020-11-19 Janssen Biotech, Inc. Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors
CN110128354A (zh) * 2019-06-20 2019-08-16 大连大学 一种5-氟-2-甲磺酰基-4-氨基嘧啶的制备方法
KR20210032093A (ko) 2019-09-16 2021-03-24 제이투에이치바이오텍 (주) Ｅｇｆｒ 돌연변이 키나제 성장 억제 효과를 나타내는 피리미딘 유도체 및 이의 의약 용도
WO2021094379A1 (en) 2019-11-12 2021-05-20 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
AU2021211871A1 (en) 2020-01-20 2022-09-08 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
JOP20220184A1 (ar) 2020-02-12 2023-01-30 Janssen Biotech Inc علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14
TW202207940A (zh) 2020-04-14 2022-03-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物
US20210369709A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
KR20210152312A (ko) * 2020-06-08 2021-12-15 주식회사 종근당 카나비노이드 수용체 (cb1 수용체) 길항제로서의 4-(4,5-디하이드로-1h-피라졸-1-닐)피리미딘 화합물 및 이를 포함하는 약제학적 조성물
KR20230069958A (ko) 2020-09-14 2023-05-19 얀센 파마슈티카 엔.브이. Fgfr 억제제 조합 요법
TWI867047B (zh) * 2020-09-18 2024-12-21 南韓商沃若諾伊公司 雜芳基衍生物、其製備方法、及含彼作為活性成份之藥學組成物
TW202227425A (zh) * 2020-09-18 2022-07-16 南韓商沃若諾伊生物公司 雜芳基衍生物、彼之製法、及包含彼作為活性成份之藥學組成物
WO2022131741A1 (ko) * 2020-12-14 2022-06-23 보로노이바이오 주식회사 아이소옥사졸리딘 유도체 화합물 및 이의 용도
EP4335847A1 (en) * 2021-05-07 2024-03-13 Voronoi Inc. Heteroaryl derivative, method for preparing same, and pharmaceutical composition comprising same as active ingredient
CA3180295A1 (en) 2021-05-17 2022-11-24 Youn Ho Lee Heteroaryl derivative compounds, and uses thereof
CN117425651A (zh) 2021-06-01 2024-01-19 杭州领业医药科技有限公司 Lazertinib甲磺酸盐的水合物晶型及其制备方法和用途
KR102685187B1 (ko) 2021-10-15 2024-07-16 제이투에이치바이오텍 (주) Alk 및/또는 egfr 돌연변이 키나제 억제 효과를 나타내는 화합물 및 이의 의약 용도
TW202342057A (zh) 2022-02-07 2023-11-01 美商健生生物科技公司 用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法
CA3255389A1 (en) 2022-03-31 2023-10-05 Astrazeneca Ab Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Combination with an AKT Inhibitor for the Treatment of Cancer
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209086A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds for treating cancer
WO2023209084A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
MA71241A (fr) 2022-06-27 2025-04-30 Astrazeneca Ab Combinaisons impliquant des inhibiteurs de tyrosine kinase du récepteur du facteur de croissance épidermique pour traiter le cancer
WO2024008929A1 (en) 2022-07-08 2024-01-11 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer
AU2023371904A1 (en) * 2022-11-03 2025-04-17 Voronoi Inc. Fumarate, tartrate, malate, and citrate salts of an egfr inhibitor
CA3228195A1 (en) 2023-05-23 2025-06-30 Janssen Biotech, Inc. Methods for treatment of non-small cell lung cancer (nsclc)
CN116655600B (zh) * 2023-05-23 2025-08-22 江南大学 一种取代的2-芳氨基嘧啶类化合物、药物组合物及其用途
WO2025017409A1 (en) 2023-07-14 2025-01-23 Janssen Biotech, Inc. Dosing regimen for therapies comprising bispecific antiegfr/c-met antibodies
WO2025052273A1 (en) 2023-09-05 2025-03-13 Janssen Biotech, Inc. Methods of treating non-small cell lung cancer

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2280515A1 (en) 1997-03-11 1998-09-17 E.I. Du Pont De Nemours And Company Heteroaryl azole herbicides
US20030004174A9 (en) 2000-02-17 2003-01-02 Armistead David M. Kinase inhibitors
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
ATE354573T1 (de) 2000-12-21 2007-03-15 Vertex Pharma ßPYRAZOLVERBINDUNGEN, DIE SICH ALS PROTEINKINASEINHIBITOREN EIGNENß
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
EA007298B1 (ru) 2001-11-01 2006-08-25 Янссен Фармацевтика Н.В. Гетероариламины в качестве ингибиторов гликогенсинтаза-киназы 3-бета (ингибиторов gsk3)
EP1565446A1 (en) 2002-11-28 2005-08-24 Schering Aktiengesellschaft Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
JP4428565B2 (ja) 2004-10-05 2010-03-10 東京エレクトロン株式会社 処理液塗布装置
AU2005295788A1 (en) 2004-10-13 2006-04-27 Wyeth N-benzenesulfonyl substituted anilino-pyrimidine analogs
EP1841760B1 (en) 2004-12-30 2011-08-10 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
US20070072894A1 (en) 2005-03-24 2007-03-29 Kempf J V Synthesis of pyrroloquinoline quinone (PQQ)
JP5007029B2 (ja) 2005-07-13 2012-08-22 Ｎｔｎ株式会社 グリース組成物および該グリース封入転がり軸受
EP1919470A1 (en) 2005-08-25 2008-05-14 F.Hoffmann-La Roche Ag FUSED PYRAZOLE AS p38 MAP KINASE INHIBITORS
JP2007117465A (ja) 2005-10-28 2007-05-17 Sharp Corp 集塵器およびそれを備えた電気掃除機
WO2007111471A1 (en) 2006-03-29 2007-10-04 Ktfreetel Co., Ltd. Digital device and method for providing additional service by using the same
MX2008012482A (es) 2006-03-31 2008-10-10 Abbott Lab Compuestos de indazol.
CN101460491A (zh) 2006-04-12 2009-06-17 惠氏公司 苯胺基嘧啶苯基和苯并噻吩类似物
EP2125781A2 (en) 2006-12-20 2009-12-02 Amgen Inc. Substituted heterocycles and methods of use
TWI458721B (zh) 2008-06-27 2014-11-01 Celgene Avilomics Res Inc 雜芳基化合物及其用途
KR101705158B1 (ko) * 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Ｅｇｆｒ 억제제 및 질환 치료방법
NZ599041A (en) * 2009-11-13 2014-05-30 Genosco Kinase inhibitors
PL2678332T3 (pl) * 2011-02-25 2016-12-30 Pochodne diaminopirymidyny i sposoby ich wytwarzania
ES2654177T3 (es) 2011-07-27 2018-02-12 Astrazeneca Ab Derivados de 2-(2,4,5-anilino sustituido)pirimidina como moduladores de EGFR útiles para tratar el cáncer
CN104203943B (zh) 2012-01-20 2017-12-29 盖诺斯克公司 取代的嘧啶化合物及其作为syk抑制剂的用途
CN104583195B (zh) * 2012-09-12 2018-08-17 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的含氮杂芳环衍生物
US8957080B2 (en) * 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
US10273224B2 (en) * 2013-08-22 2019-04-30 Jubilant Biosys Limited Substituted pyrimidine compounds, compositions and medicinal applications thereof
WO2015094803A1 (en) 2013-12-16 2015-06-25 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
CN104860941B (zh) 2014-02-25 2017-03-22 上海海雁医药科技有限公司 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
CN111892579B (zh) 2014-06-12 2023-07-25 上海艾力斯医药科技股份有限公司 一类激酶抑制剂
BR112016029662B1 (pt) 2014-06-19 2023-10-24 Takeda Pharmaceutical Company Limited COMPOSTO DE FÓRMULA Bf OU UMA FORMA FARMACEUTICAMENTE ACEITÁVEL DO MESMO, COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO O MESMO E SEU USO
HRP20250213T1 (hr) * 2014-10-13 2025-04-25 Yuhan Corporation Spojevi i pripravci za modulaciju aktivnosti egfr mutantne kinaze
CN104788427B (zh) * 2015-02-05 2017-05-31 上海泓博智源医药股份有限公司 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用

Also Published As

Publication number Publication date
RS61865B1 (sr) 2021-06-30
KR102208775B1 (ko) 2021-01-28
RU2017116598A (ru) 2018-11-21
KR102487451B1 (ko) 2023-01-11
DK3207035T3 (da) 2020-01-27
HUE048006T2 (hu) 2020-05-28
EP3207035A2 (en) 2017-08-23
BR112017007769B1 (pt) 2023-10-10
BR112017007769A2 (pt) 2018-01-16
MX385942B (es) 2025-03-18
CA2962914A1 (en) 2016-04-21
SI3207035T1 (sl) 2020-04-30
DK3604294T3 (da) 2021-06-28
LT3929190T (lt) 2025-02-25
KR20200014944A (ko) 2020-02-11
CY1124359T1 (el) 2022-07-22
CN111686110B (zh) 2023-06-16
MX2021010761A (es) 2022-06-09
PT3604294T (pt) 2021-07-29
EP3207035B1 (en) 2019-11-20
PT3207035T (pt) 2020-02-19
DK3929190T3 (da) 2025-02-24
JP2020196740A (ja) 2020-12-10
SMT202500069T1 (it) 2025-03-12
EP4421069A1 (en) 2024-08-28
ES3009926T3 (en) 2025-03-31
RU2727700C2 (ru) 2020-07-23
NZ730012A (en) 2019-06-28
US9593098B2 (en) 2017-03-14
CY1122737T1 (el) 2021-03-12
WO2016060443A2 (en) 2016-04-21
HRP20250213T1 (hr) 2025-04-25
AU2015331166A1 (en) 2017-03-30
FIC20250023I1 (fi) 2025-06-06
LTPA2025522I1 (enExample) 2025-06-25
EP3929190B1 (en) 2024-12-25
RS59900B1 (sr) 2020-03-31
RU2020123547A (ru) 2020-08-18
KR20230010836A (ko) 2023-01-19
EP3604294A1 (en) 2020-02-05
HUS2500023I1 (hu) 2025-06-28
SG11201701960XA (en) 2017-04-27
EP4421069B1 (en) 2025-12-10
PL3604294T3 (pl) 2021-11-02
PT3929190T (pt) 2025-02-19
EP3207035A4 (en) 2018-03-14
AU2015331166B2 (en) 2018-04-26
CA2962914C (en) 2018-10-23
CN106795144B (zh) 2020-06-16
CN111686110A (zh) 2020-09-22
RU2017116598A3 (enExample) 2018-11-21
HUE070874T2 (hu) 2025-07-28
RS66529B1 (sr) 2025-03-31
JP2019163277A (ja) 2019-09-26
TW201938553A (zh) 2019-10-01
NL301329I2 (nl) 2025-09-09
LT3207035T (lt) 2020-02-25
SI3604294T1 (sl) 2021-08-31
KR102662358B1 (ko) 2024-04-30
PL3929190T3 (pl) 2025-06-09
ES2770058T3 (es) 2020-06-30
SI3929190T1 (sl) 2025-04-30
SMT202100266T1 (it) 2021-07-12
LT3604294T (lt) 2021-07-26
NO2025025I1 (no) 2025-06-05
EP3929190A1 (en) 2021-12-29
CN106795144A (zh) 2017-05-31
KR102073854B1 (ko) 2020-02-05
TW201619150A (zh) 2016-06-01
PH12017500488A1 (en) 2017-07-31
PL3207035T3 (pl) 2020-06-01
ES2879474T3 (es) 2021-11-22
MX2020002168A (es) 2021-09-07
HUE054848T2 (hu) 2021-09-28
EP3604294B1 (en) 2021-05-05
MX2017003181A (es) 2017-07-20
TWI730331B (zh) 2021-06-11
KR20170066650A (ko) 2017-06-14
KR20240074820A (ko) 2024-05-28
US20160102076A1 (en) 2016-04-14
TWI664173B (zh) 2019-07-01
KR20210011068A (ko) 2021-01-29
JP6524221B2 (ja) 2019-06-05
JP2017530999A (ja) 2017-10-19
HRP20210949T1 (hr) 2021-09-03
HRP20200201T1 (hr) 2020-05-15
FI3929190T3 (fi) 2025-02-28
JP6754864B2 (ja) 2020-09-16
SMT202000059T1 (it) 2020-03-13
WO2016060443A3 (en) 2016-06-23
USRE50528E1 (en) 2025-08-12

Similar Documents

Publication Publication Date Title
FR25C1021I1 (fr) Composés et compositions destinés à moduler les activités kinase de l'egfr mutant
FR21C1039I2 (fr) Composés destinés à traiter l'amyotrophie spinale
EP3464275A4 (en) EGFR INHIBITOR COMPOUNDS
DK3386511T3 (da) Fremgangsmåder til behandling af huntingtons sygdom
ME03334B (me) Heteroarilna jedinjenja za inhibiciju kinaza
EP3250035A4 (en) COMPOUNDS AND THEIR USE AS BACE-1 INHIBITORS
IL271144A (en) Methods and compositions for reducing the immunogenicity of chimeric notch receptors
DK3720433T3 (da) Bis-cholin-tetrathiomolybdat til behandling af wilsons sygdom
EP3347334A4 (en) DEHYDROHALOGENICATION OF FLUOROCHOLE HYDROGEN
EP3152190C0 (en) BI-POLYCYCLIC COMPOUNDS WITH 18-20 ELEMENTS
EP3463259A4 (en) SUN PROTECTION COMPOSITIONS
EP3512518A4 (en) BUPRENORPHINE FORMULAS WITH DELAYED RELEASE
MA43764A (fr) Inhibiteur monovalent de l'interaction hutnfr1
EP3718414A4 (en) EMULSION COMPOSITION
EP3568203C0 (en) Compounds and compositions
EP3458432A4 (en) FERTILIZER COMPOSITION
EP3416672A4 (en) Oritavancin FORMULATIONS
EP3352778A4 (en) METHODS, COMPOUNDS AND COMPOSITIONS FOR MODULATING THE BLOOD-BRAIN BARRIER INTEGRITY AND REMYELINISATION
EP3364976A4 (en) PIPERAZINYL-NORBENZOMORPHAN COMPOUNDS AND METHOD FOR USE THEREOF
EP3459223A4 (en) ERLAUBNISDELEGIERUNGSRAHMENWERK
EP3395343A4 (en) Vasopressin-like action enhancer
FR3056541B1 (fr) Douille cisaillable d'attelage ferroviaire
EP3335729A4 (en) ETANERCEPT COMPOSITION WITH IMPROVED STABILITY
FR3036757B1 (fr) Disque d'embrayage
FR3036756B1 (fr) Disque d'embrayage